Keywords
antithrombotic therapy
early therapy
management
outcomes
rate control
rhythm control
risk factors
How to Cite
Abstract
Atrial fibrillation (AF) is a global health problem. The condition brings an increased risk of stroke, systemic embolism, and heart failure and is associated with impaired quality of life, frequent hospitalizations, and mortality. Prevention of AF-related complications relies on antithrombotic therapy, control of ventricular rate, and adequate therapy of concomitant cardiac diseases. Long-term antithrombotic therapy should be guided by the patient’s risk for thromboembolism, after an evaluation of the bleeding risk, and a discussion of the pros and cons and the patient preferences. Symptoms related to AF are an important determinant in making the decision to opt for rate- or rhythm-control in addition to factors that may influence the success of rhythm control. Therefore, setting a successful patient-tailored therapeutic strategy can be a challenging goal to achieve. This review provides a comprehensive overview of the management of atrial fibrillation in the light of the latest 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines and the 2012 focused update of the European Society of Cardiology guidelines.
References
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071-104.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. ESC Committee for Practice Guidelines(CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719-47.
Taboulet P, Duchenne J, Lefort H, Zanker C, Jabre P, Davy JM, et al. Prise en charge de la fibrillation atriale en médecine d’urgence. Recommandations de la Société française de médecine d’urgence en partenariat avec la Société française de cardiologie. Ann Fr Med Urgence 2015; 5:260-79.
Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31:967-75.
Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008; 29:2125-32.
Heeringa J, Van der Kuip DA, Hofman A, Kors JA, van Herpen J, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27:949-53.
Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946-52.
Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007; 370:604-18.
Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 2007; 115:3050-6.
Mason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K, et al. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med 2012; 125:603-6.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 2010; 138:1093-100.
Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 2007; 370:493-503.
Lip GYH, Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012; 60:738-746.
Bhargava K. Atrial Fibrillation Part II: Rate and Rhythm-Control Strategies of Management. J Clin Prev Cardiol 2014; 3:85-92.
Alboni P, Botto G.L, Baldi N, Luzi M, Russo V, Gianfranchi L, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 2004; 351:2384-91.
Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O’Neill G, Sharma A, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004; 43:1201-8.